CY1105796T1 - Θepαπεια οξεωσης της μεγαλης κοιλιας των μηρυκαστικων με αναστολεις αλφα-αμυλασης - Google Patents
Θepαπεια οξεωσης της μεγαλης κοιλιας των μηρυκαστικων με αναστολεις αλφα-αμυλασηςInfo
- Publication number
- CY1105796T1 CY1105796T1 CY20061101681T CY061101681T CY1105796T1 CY 1105796 T1 CY1105796 T1 CY 1105796T1 CY 20061101681 T CY20061101681 T CY 20061101681T CY 061101681 T CY061101681 T CY 061101681T CY 1105796 T1 CY1105796 T1 CY 1105796T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ruminant
- amylase
- bacterial
- glucosidase
- acidosis
- Prior art date
Links
- 241000282849 Ruminantia Species 0.000 title abstract 6
- 239000003392 amylase inhibitor Substances 0.000 title abstract 2
- 102000004139 alpha-Amylases Human genes 0.000 abstract 6
- 108090000637 alpha-Amylases Proteins 0.000 abstract 6
- 229940024171 alpha-amylase Drugs 0.000 abstract 6
- 230000001580 bacterial effect Effects 0.000 abstract 6
- 208000010444 Acidosis Diseases 0.000 abstract 5
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract 5
- 230000007950 acidosis Effects 0.000 abstract 5
- 208000026545 acidosis disease Diseases 0.000 abstract 5
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- -1 hydrate) Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Sustainable Development (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Birds (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fodder In General (AREA)
- Saccharide Compounds (AREA)
- Feed For Specific Animals (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η εφεύρεση που περιγράφεται εδώ αφορά: τη χρήση ενός αποτελεσματικού αναστολέα μιας βακτηριακής α-αμυλάσης ή/και α-γλυκοσιδάσης στη βιομηχανική κατασκευή μιας σύνθεσης για τη θεραπεία οξέωσης, μέθοδο θεραπείας οξέωσης της μεγάλης κοιλίας των μηρυκαστικών, που περιλαμβάνει χορήγηση αποτελεσματικής ποσότητας ενός αποτελεσματικού αναστολέα μιας βακτηριακής α-αμυλάσης ή/και α-γλυκοσιδάσης σε ένα μηρυκαστικό, συνταγοποίηση κατάλληλη για τη θεραπεία οξέωσης σε ένα ζώο, που περιλαμβάνει αποτελεσματικό αναστολέα μιας βακτηριακής α-αμυλάσης ή/και α-γλυκοσιδάσης σε ανάμιξη με ένα κατάλληλο έκδοχο, διαλύτη ή φορέα, που επιλέγεται σε σχέση με τον επιδιωκόμενο τρόπο χορήγησης και την πρότυπη φαρμακευτική/κτηνιατρική/αγροκτήματος πρακτική, μεθόδους λεπτομερούς εξέτασης χρήσιμες στην πιστοποίηση ενός κατάλληλου αναστολέα μιας βακτηριακής α-αμυλάσης ή/και α-γλυκοσιδάσης για τη θεραπεία οξέωσης σε ένα μηρυκαστικό, μέθοδο για βελτίωση της ποιότητας γάλακτος ή/και της ποσότητας μηρυκαστικού, που περιλαμβάνει θεραπεία ενός μηρυκαστικού με μια αποτελεσματική ποσότητα ενός αναστολέα βακτηριακής α-αμυλάσης ή/και α-γλυκοσιδάσης, μια ένωση του τύπου I:ή κτηνιατρικώς αποδεκτό άλας, διαλύτωμα (συμπεριλαμβανομένου υδρίτη) ή προφαρμάκου αυτής και μεθόδους για να κατασκευάζεται ένας αποτελεσματικός αναστολέας μιας βακτηριακής α-αμυλάσης ή/και α-γλυκοσιδάσης χρήσιμος για τη θεραπεία οξέωσης σε ένα μηρυκαστικό.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0012760A GB0012760D0 (en) | 2000-05-24 | 2000-05-24 | Treatment |
| GB0012793A GB0012793D0 (en) | 2000-05-24 | 2000-05-24 | Treatment |
| GB0017495A GB0017495D0 (en) | 2000-07-17 | 2000-07-17 | Treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105796T1 true CY1105796T1 (el) | 2011-02-02 |
Family
ID=27255738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101681T CY1105796T1 (el) | 2000-05-24 | 2006-11-17 | Θepαπεια οξεωσης της μεγαλης κοιλιας των μηρυκαστικων με αναστολεις αλφα-αμυλασης |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050233983A1 (el) |
| EP (2) | EP1157696B1 (el) |
| JP (2) | JP3798261B2 (el) |
| KR (1) | KR100643946B1 (el) |
| AT (1) | ATE343391T1 (el) |
| AU (1) | AU785303B2 (el) |
| CA (1) | CA2348245C (el) |
| CY (1) | CY1105796T1 (el) |
| DE (1) | DE60124030T2 (el) |
| DK (1) | DK1157696T3 (el) |
| ES (1) | ES2272418T3 (el) |
| HU (1) | HUP0102159A3 (el) |
| IL (2) | IL186223A0 (el) |
| MY (1) | MY136145A (el) |
| NZ (1) | NZ511877A (el) |
| PT (1) | PT1157696E (el) |
| TW (1) | TWI298021B (el) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60124030T2 (de) * | 2000-05-24 | 2007-04-12 | Pfizer Inc. | Behandlung von Pansenacidose mit Amylasehemmern |
| US7906128B2 (en) * | 2002-10-21 | 2011-03-15 | Wyeth Llc | Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals |
| US7108869B2 (en) * | 2002-11-07 | 2006-09-19 | Access Business Group International Llc | Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors |
| CN1296050C (zh) * | 2003-12-10 | 2007-01-24 | 浙江海正药业股份有限公司 | 阿卡波糖肠溶片及制备方法 |
| CN101235061B (zh) * | 2007-09-11 | 2011-03-30 | 南开大学 | 一类新的α-淀粉酶抑制剂阿卡他定系列化合物及其应用 |
| US8791245B2 (en) * | 2008-10-03 | 2014-07-29 | Glycan Bioscience LLC | Anionic conjugates of glycosylated bacterial metabolite |
| DE102009015558B4 (de) * | 2009-03-30 | 2017-04-27 | Ulf-Michael Stumpe | Bollus zum Eingeben in die Vormägen von Wiederkäuern zur Verbesserung der Vormagenaktivität und Vormagengesundheit |
| US20130164275A1 (en) * | 2009-10-26 | 2013-06-27 | Pharmachem Laboratories, Inc. | Method for treating acidosis in ruminants |
| CN102212089A (zh) * | 2011-04-12 | 2011-10-12 | 天津医科大学 | 一类新的α-淀粉酶抑制剂阿卡他定家族新化合物及其应用 |
| EP3375453A1 (de) * | 2017-03-13 | 2018-09-19 | Basf Se | Verwendung einer pansengeschützen alpha-amylase |
| WO2020118345A1 (en) * | 2018-12-14 | 2020-06-18 | ProAgni Pty Ltd | Animal feed composition |
| CN110899293A (zh) * | 2019-10-15 | 2020-03-24 | 上海交通大学 | 一种对阿卡波糖废渣减量化处理的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4062950A (en) * | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
| DE2658562A1 (de) * | 1976-12-23 | 1978-10-12 | Bayer Ag | Aminozuckerderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| US4175123A (en) * | 1976-12-23 | 1979-11-20 | Bayer Aktiengesellschaft | Amino-sugar derivatives, process for their preparation and pharmaceutical composition thereof |
| CA1121290A (en) * | 1978-02-14 | 1982-04-06 | Yasuji Suhara | Amino sugar derivatives |
| EP0173950A3 (de) * | 1984-09-04 | 1987-10-28 | Hoechst Aktiengesellschaft | Neuer alpha-Glukosidase Inhibitor, Verfahren zur seiner Herstellung, seine Verwendung und pharmazeutische Präparate |
| DE3543999A1 (de) * | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
| US4885361A (en) * | 1987-07-31 | 1989-12-05 | Hoffmann-La Roche Inc. | Sulfated oligosaccharides |
| US5021427A (en) * | 1988-12-23 | 1991-06-04 | The Board Of Regents, The University Of Texas System | Novel pyrrolizidine alkaloid |
| WO1999026606A2 (en) * | 1997-11-25 | 1999-06-03 | Bayer Aktiengesellschaft | SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS |
| US7022684B2 (en) * | 2000-05-24 | 2006-04-04 | Pfizer Inc. | Treatment of rumen acidosis with α-amylase inhibitors |
| DE60124030T2 (de) * | 2000-05-24 | 2007-04-12 | Pfizer Inc. | Behandlung von Pansenacidose mit Amylasehemmern |
-
2001
- 2001-05-17 DE DE60124030T patent/DE60124030T2/de not_active Expired - Lifetime
- 2001-05-17 AT AT01304379T patent/ATE343391T1/de active
- 2001-05-17 EP EP01304379A patent/EP1157696B1/en not_active Expired - Lifetime
- 2001-05-17 IL IL186223A patent/IL186223A0/en unknown
- 2001-05-17 EP EP06122716A patent/EP1745790A3/en not_active Withdrawn
- 2001-05-17 IL IL143225A patent/IL143225A/en not_active IP Right Cessation
- 2001-05-17 PT PT01304379T patent/PT1157696E/pt unknown
- 2001-05-17 DK DK01304379T patent/DK1157696T3/da active
- 2001-05-17 ES ES01304379T patent/ES2272418T3/es not_active Expired - Lifetime
- 2001-05-21 TW TW090112057A patent/TWI298021B/zh not_active IP Right Cessation
- 2001-05-22 MY MYPI20012401A patent/MY136145A/en unknown
- 2001-05-22 AU AU46192/01A patent/AU785303B2/en not_active Ceased
- 2001-05-22 CA CA002348245A patent/CA2348245C/en not_active Expired - Fee Related
- 2001-05-23 HU HU0102159A patent/HUP0102159A3/hu unknown
- 2001-05-23 KR KR1020010028269A patent/KR100643946B1/ko not_active IP Right Cessation
- 2001-05-23 NZ NZ511877A patent/NZ511877A/xx not_active IP Right Cessation
- 2001-05-24 JP JP2001155771A patent/JP3798261B2/ja not_active Expired - Fee Related
-
2004
- 2004-12-30 US US11/026,459 patent/US20050233983A1/en not_active Abandoned
-
2005
- 2005-05-30 JP JP2005157591A patent/JP2005336192A/ja active Pending
-
2006
- 2006-11-17 CY CY20061101681T patent/CY1105796T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1157696T3 (da) | 2007-02-12 |
| EP1745790A3 (en) | 2007-03-21 |
| KR100643946B1 (ko) | 2006-11-10 |
| CA2348245C (en) | 2007-12-11 |
| IL143225A0 (en) | 2002-04-21 |
| KR20010107661A (ko) | 2001-12-07 |
| PT1157696E (pt) | 2007-01-31 |
| MY136145A (en) | 2008-08-29 |
| HUP0102159A2 (hu) | 2002-01-28 |
| EP1745790A2 (en) | 2007-01-24 |
| ATE343391T1 (de) | 2006-11-15 |
| JP2005336192A (ja) | 2005-12-08 |
| IL186223A0 (en) | 2008-01-20 |
| DE60124030T2 (de) | 2007-04-12 |
| IL143225A (en) | 2008-03-20 |
| EP1157696A2 (en) | 2001-11-28 |
| AU4619201A (en) | 2001-11-29 |
| AU785303B2 (en) | 2007-01-04 |
| HU0102159D0 (en) | 2001-08-28 |
| US20050233983A1 (en) | 2005-10-20 |
| DE60124030D1 (de) | 2006-12-07 |
| EP1157696B1 (en) | 2006-10-25 |
| CA2348245A1 (en) | 2001-11-24 |
| EP1157696A3 (en) | 2002-02-13 |
| ES2272418T3 (es) | 2007-05-01 |
| TWI298021B (en) | 2008-06-21 |
| NZ511877A (en) | 2002-11-26 |
| JP2002047209A (ja) | 2002-02-12 |
| JP3798261B2 (ja) | 2006-07-19 |
| HUP0102159A3 (en) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105796T1 (el) | Θepαπεια οξεωσης της μεγαλης κοιλιας των μηρυκαστικων με αναστολεις αλφα-αμυλασης | |
| DE60319967D1 (de) | Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen | |
| BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
| CY1105000T1 (el) | Χρηση της σπινοσαδης ή μιας συνθεσεως περιεχουσης σπινοσαδη | |
| EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
| EA200300354A1 (ru) | Хинолиноновые производные в качестве ингибиторов тирозинкиназы | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| TR200302242T2 (tr) | Protein kinaz önleyicileri olarak pirolopirimidinler | |
| CY1108813T1 (el) | Αναστολεις κινασων τυροσινης | |
| NO974589D0 (no) | Farmasöytisk preparat inneholdende protonpumpeinhibitorer | |
| ATE204873T1 (de) | Naphthyridinderivate als angiotensin-ii- antagonist-inhibitoren | |
| TNSN94035A1 (fr) | Composition veterinaire | |
| NO20051966L (no) | Nye pyrimidinamidderivater og anvendelse derav | |
| JP6629327B2 (ja) | 微生物感染の予防または治療で使用される組み合わせ | |
| DE60134245D1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
| TR199701647A2 (xx) | �kame edilmi� purin t�revleri,bunlar�n imalat usul� | |
| AR018501A1 (es) | Derivados de la dolastatina 15 | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| PA8485601A1 (es) | Azalidas de 13 miembros y su uso como agentes antibioticos. | |
| US8008093B2 (en) | Inhibition of Hsp27 phosphorylation for the treatment of blistering disorders | |
| SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| EA200601249A1 (ru) | Пиперазины, пригодные для лечения боли | |
| Khazaeil et al. | Enrofloxacin effect on histomorphologic and histomorphometric structure of lamb articular cartilage | |
| CN113082030B (zh) | 一种药物组合物及其应用 | |
| ATE425756T1 (de) | Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten |